[ASBMR 2010 report. Meeting report on the ASBMR. Present and future of the treatment of osteoporosis].
ASBMR meeting 2011 had been held in San Diego, CA from September 16th to 20th 2011. Identification of new risk factors for osteoporosis or the long-term result of novel medicine in clinical trials was presented. Also the hot discussion as to the updated recommendations of the US Institute of Medicine (IOM) on the intake of vitamin D was done.
Department of Rheumatosurgery, Osaka City University Medical School, Japan.
Tatsuya
T
Koike
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001690:Biological Science Disciplines / Q000458:organization & administration*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D000069448:Denosumab; D004164:Diphosphonates / Q000008:administration & dosage; D006801:Humans; D058990:Molecular Targeted Therapy; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D053245:RANK Ligand / Q000276:immunology; D012307:Risk Factors; D012958:Societies, Scientific / Q000458:organization & administration*; D014481:United States; D014807:Vitamin D / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D014807:Vitamin D; D000069448:Denosumab